Suppression of aortic atherosclerosis in cholesterol-fed rabbits by purified rabbit interferon.
The effectiveness of rabbit interferon in suppressing atherosclerosis was evaluated in rabbits fed a diet containing 1% cholesterol. Ten male New Zealand White rabbits received intramuscular injections of 1 million units of interferon twice a week, while a control group of 10 rabbits received injections of buffer. Both groups had average serum cholesterol levels of over 2000 mg/dl during the 8-week experimental period. Interferon treatment resulted in no significant hypolipidemic effect or changes in lipoprotein composition. Atherosclerotic lesions in aortas were quantified both macroscopically and microscopically. Interferon treatment decreased the grossly visible lesion area significantly from 25 +/- 4% to 8 +/- 1% (mean +/- SEM, p less than 0.005) compared to the untreated group. Microscopic analysis of serial cross-sections of aortic segments revealed significant (p less than 0.01) reductions in both lesion size and frequency in the interferon-treated group. Electron microscopy also showed that interferon treatment reduced the pathological effects of cholesterol feeding. Tissue analysis showed that total aortic cholesterol was reduced by 28% by interferon treatment, while the aortic phospholipid concentration was increased by 25%. The possibility exists that the interferon preparation used contained other biological response modifiers and that the observed effects may be totally unrelated with interferon. These results suggest that the mechanism of atherosclerosis suppression in these cholesterol-fed rabbits is not related to the lowering of serum cholesterol but may be associated with inhibition of lesion initiation.
University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick 08903.
A C
AC
Wilson
R G
RG
Schaub
R C
RC
Goldstein
P T
PT
Kuo
D000311:Adrenal Glands / Q000648:ultrastructure; D000704:Analysis of Variance; D000818:Animals; D001011:Aorta / Q000648:ultrastructure; D001018:Aortic Diseases / Q000097:blood / Q000473:pathology / Q000517:prevention & control*; D001161:Arteriosclerosis / Q000097:blood / Q000473:pathology / Q000517:prevention & control*; D002791:Cholesterol, Dietary; D004195:Disease Models, Animal; D006801:Humans; D007372:Interferons / Q000494:pharmacology*; D007668:Kidney / Q000648:ultrastructure; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008099:Liver / Q000648:ultrastructure; D008264:Macrophages / Q000378:metabolism; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D013154:Spleen / Q000648:ultrastructure
D002791:Cholesterol, Dietary; D008055:Lipids; D008074:Lipoproteins; D007372:Interferons